Table 2.
Uni- and multivariate analyses of clinical parameters on progress-free survival to immunotherapy.
| Factors | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | |
| Sex (Female/Male) | 0.89 (0.42–1.91) | 0.77 | ||
| Age (<65/≥65) | 0.82 (0.34–1.96) | 0.66 | ||
| Smoking (Never/Smoking) | 0.65 (0.25–1.74) | 0.39 | ||
| PS (0–1/2) | 0.49 (0.23–1.07) | 0.07★ | 0.62 (0.26–1.44) | 0.27 |
| Histology (Adno/Non-adeno | 0.57 (0.076–4.21) | 0.58 | ||
| EGFR type (19DEL/L858R) | 1.25 (0.59–2.65) | 0.55 | ||
| EGFR T790M (positive/negative) | 0.709 (0.273–1.841) | 0.46 | ||
| Stage (III/IV) | 0.67 (0.15–2.92) | 0.59 | ||
| Distant metastasis (Yes/No) | 0.67 (0.15–2.92) | 0.59 | ||
| Regimen of EGFR-TKIs | ||||
| Gefitinib | 1 | |||
| Erlotinib | 0.71 (0.29–1.73) | 0.45 | ||
| Icotinib | 1.08 (0.31–3.82) | 0.9 | ||
| PFS to EGFR-TKIs | ||||
| <10 months | 1.00 | 1 | ||
| ≥10 months | 5.17 (2.05–13.0) | 0.000***★ | 5.93 (2.21–15.89) | 0.000*** |
| No. of immunotherapy line (2/≥3) | 1.36 (0.88–2.08) | 0.16★ | 1.46 (0.94–2.27) | 0.09 |
| Regimen of immunotherapy, n(%) | ||||
| αPD-1 monotherapy | 1 | 1 | ||
| αPD-1 + Chemo | 0.48 (0.18–1.29) | 0.15★ | 0.33 (0.11–0.96) | 0.043* |
| αPD-1 + Apatinib | 0.27 (0.03–2.35) | 0.24 | 0.14 (0.015–1.24) | 0.08 |
| PD-L1 expression (Positive/Negative) | 0.81 (0.31–2.11) | 0.67 | ||
| Radiotherapy (Yes/No) | 1.11 (0.46–2.66) | 0.82 | ||
Same as in Table 1 . ★ < 0.02, ***p < 0.001.